Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value
$4.06−0.25 (-5.80%)
Close on Nov 12, 2026Market cap $337.78MP/E –Yield –
Opus Genetics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Opus Genetics's EV/EBITDA was 0.6× on Jan 31, 2024.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jan 31, 2024 | 0.6× | −0.3 |
| 2023 | Dec 29, 2023 | 0.9× | – |
See a number that looks wrong?